Center for accelerated development of drug candidates targeting high threat bacterial infections

Antimicrobial resistance (AMR) is a growing global health crisis that threatens the effectiveness of existing treatments and increases rates of illness and death. In response to this urgent challenge, this Bacterial Center of Excellence for Translational Research (Bacterial CETR) (1U19AI189168-01) funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), is dedicated to accelerating the development of innovative antibiotic candidates designed to combat drug-resistant bacteria. Through strategic academic-industry partnerships (Figure), we aim to advance five programs with the goal of delivering multiple investigational new drugs (INDs) ready for clinical evaluation. Our mission is to drive the discovery and development of next-generation antibiotics that can meet the critical need for effective treatment options in the face of rising resistance.